GCC19CART

N/A

Report date: 2026/02/28 20:00:37

Base Information

Drug NameGCC19CART
Drug Alias NameGCC19CARTLYL273LYL-273
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionHeat-stable enterotoxin receptor antagonists
TargetsHeat-stable enterotoxin receptor
Therapy Area/IndicationsRectal NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesInnovative Cellular Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLyell Immunopharma IncInnovative Cellular Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsRectal NeoplasmsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A